Anti-PD-1/LAG3 bispecific antibodies
View Patent ↗Provided herein are anti-PD-1/LAG3 bispecific antibodies and antigen-binding fragments. Also provided here are methods and uses of these antibodies and antigen-binding fragments in the treatment of cancer or infectious disease.
1. An anti-PD-1/LAG-3 bispecific antibody comprising:
(A) an anti-PD-1 antigen-binding fragment comprising:
(i) a heavy chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO:8,
(ii) a heavy chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO:91,
(iii) a heavy chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO:10,
(iv) a light chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO:3,
(v) a light chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO:21, and
(vi) a light chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO:22; and
(B) an anti-LAG3 antigen-binding fragment comprising:
(i) a heavy chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO:112,
(ii) a heavy chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO:113,
(iii) a heavy chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO:114,
(iv) a light chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO:115,
(v) a light chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO:116, and
(vi) a light chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO:117.
2. The anti-PD-1/LAG-3 bispecific antibody of claim 1 , wherein the anti-PD-1 heavy chain variable region CDR2 comprises the amino acid sequence of SEQ ID NO:86.
3. An anti-PD-1/LAG-3 bispecific antibody comprising
(A) an anti-PD-1 antigen-binding fragment comprising a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:92, and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:14, 17, 20, 24, 28, 31, or 34; and
(B) an anti-LAG3 antigen-binding fragment comprising an anti-LAG3 heavy chain variable region comprising the amino acid sequence of SEQ ID NO:97, and a light chain variable region comprising the amino acid sequence of SEQ ID NO:99.
4. The anti-PD-1/LAG-3 bispecific antibody of claim 3 , wherein the anti-PD-1 antigen-binding fragment comprises a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:92, and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:20.
5. The anti-PD-1/LAG-3 bispecific antibody of claim 3 , wherein the anti-PD-1 antigen-binding fragment comprises a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:85, and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:20.
6. The anti-PD-1/LAG-3 bispecific antibody of claim 4 , comprising:
(A) an anti-PD-1 antigen-binding fragment comprising (i) a heavy chain comprising a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:92, and an IgG1 constant region comprising CH1 mutations 145E, 147T, 175E, and 183L, and CH3 mutations 350V, 351Y, 405A, and 407V, and (ii) a light chain comprising a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:20, and a kappa constant region comprising C κ mutations 124R and 178R; and
(B) an anti-LAG3 antigen-binding fragment comprising (i) a heavy chain comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:97, and an IgG1 constant region comprising CH1 mutation 181K, and CH3 mutations 350V, 366L, 392L, and 394W, and (ii) a light chain comprising a light chain variable region comprising the amino acid sequence of SEQ ID NO:99, and a kappa constant region comprising C κ mutations 124E, 131T, 178Y, and 180E,
wherein the mutations are in EU numbering.
7. The anti-PD-1/LAG-3 bispecific antibody of claim 4 , comprising:
(A) an anti-PD-1 antigen-binding fragment comprising (i) a heavy chain comprising a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:92, and an IgG1 constant region comprising CH1 mutations 145E, 147T, 175E, and 183L, and CH3 mutations 350V, 366L, 392L, and 394W, and (ii) a light chain comprising a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:20, and a kappa constant region comprising C κ mutations 124R and 178R; and
(B) an anti-LAG3 antigen-binding fragment comprising (i) a heavy chain comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:97 and an IgG1 constant region comprising CH1 mutation 181K, and CH3 mutations 350V, 351Y, 405A, and 407V, and (ii) a light chain comprising a light chain variable region comprising the amino acid sequence of SEQ ID NO:99, and a kappa constant region comprising C κ mutations 124E, 131T, 178Y, and 180E;
wherein the mutations are in EU numbering.
8. The anti-PD-1/LAG-3 bispecific antibody of claim 4 , comprising:
(A) an anti-PD-1 antigen-binding fragment comprising (i) a heavy chain comprising a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:92, and an IgG1 constant region comprising CH1 mutations 145E, 147T, 175E, and 183L, and (ii) a light chain comprising a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:20, and a kappa constant region comprising C κ mutations 124R and 178R; and
(B) an anti-LAG3 antigen-binding fragment comprising (i) a heavy chain comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:97, and an IgG1 constant region comprising CH1 mutation 181K, and (ii) a light chain comprising a light chain variable region comprising the amino acid sequence of SEQ ID NO:99, and a kappa constant region comprising C κ mutations 124E, 131T, 178Y, and 180E;
wherein the IgG1 heavy chain constant regions of the anti-PD-1 and anti-LAG3 antigen-binding fragments further comprise pairs of CH3 mutations selected from the group consisting of: 351Y/405A/407V and 366I/392M/394W; 351Y/405A/407V and 366L/392L/394W; 351Y/405A/407V and 366L/392M/394W, and
wherein the mutations are in EU numbering.
9. The anti-PD-1/LAG-3 bispecific antibody of claim 3 , comprising:
(A) an anti-PD-1 antigen-binding fragment comprising (i) a heavy chain comprising a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:92, and an IgG1 constant region comprising CH1 mutations 145E, 147T, 175E, and 183L, and CH3 mutations 350V, 351Y, 405A, and 407V, and (ii) a light chain comprising a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:14, 17, 20, 24, 28, 31, or 34, and a kappa constant region comprising C κ mutations 124R and 178R; and
(B) an anti-LAG3 antigen-binding fragment comprising (i) a heavy chain comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:97, and an IgG1 constant region comprising CH1 mutation 181K, and CH3 mutations 350V, 366L, 392L, and 394W, and (ii) a light chain comprising a light chain variable region comprising the amino acid sequence of SEQ ID NO:99, and a kappa constant region comprising C κ mutations 124E, 131T, 178Y, and 180E,
wherein the mutations are in EU numbering.
10. An anti-PD-1/LAG3 bispecific antibody, comprising:
(A) an anti-PD-1 heavy chain comprising the amino acid sequence of SEQ ID NO:102, and a light chain comprising the amino acid sequence of SEQ ID NO:103, and
(B) an anti-LAG3 heavy chain comprising the amino acid sequence of SEQ ID NO:96, and a light chain comprising the amino acid sequence of SEQ ID NO:98.
11. An anti-PD-1/LAG-3 bispecific antibody comprising:
(A) an anti-PD-1 antigen-binding fragment comprising:
(i) a heavy chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO:8,
(ii) a heavy chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO:86,
(iii) a heavy chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO:10 or 41,
(iv) a light chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO:3,
(v) a light chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO:4, and
(vi) a light chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO:5; and
(B) an anti-LAG3 antigen-binding fragment comprising:
(i) a heavy chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO:112,
(ii) a heavy chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO:113,
(iii) a heavy chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO:114,
(iv) a light chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO:115,
(v) a light chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO:116, and
(vi) a light chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO:117.
12. The anti-PD-1/LAG-3 bispecific antibody of claim 11 , wherein
(A) the anti-PD-1 antigen-binding fragment comprises a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:95, and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:76; and
(B) the anti-LAG3 antigen-binding fragment comprises an anti-LAG3 heavy chain variable region comprising the amino acid sequence of SEQ ID NO:97, and light chain variable region comprising the amino acid sequence of SEQ ID NO:99.
13. An anti-PD-1/LAG-3 bispecific antibody comprising:
(A) an anti-PD-1 antigen-binding fragment comprising (i) a heavy chain comprising a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:93, and an IgG1 constant region comprising CH1 mutations 145E, 147T, 175E, and 183L, and CH3 mutations 350V, 351Y, 405A, and 407V, and (ii) a light chain comprising a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:76, and a kappa constant region comprising C κ mutations Q124R and T178R; and
(B) an anti-LAG3 antigen-binding fragment comprising (i) a heavy chain comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:97, and an IgG1 constant region comprising CH1 mutation 181K, and CH3 mutations 350V, 366L, 392L, and 394W, and (ii) a light chain comprising a light chain variable region comprising the amino acid sequence of SEQ ID NO:99, and a kappa constant region comprising C κ mutations 124E, 131T, 178Y, and 180E, wherein the mutations are in EU numbering.
14. An anti-PD-1/LAG-3 bispecific antibody comprising:
(A) an anti-PD-1 antigen-binding fragment comprising (i) a heavy chain comprising a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:93, and an IgG1 constant region comprising CH1 mutations 145E, 147T, 175E, and 183L, and CH3 mutations 350V, 366L, 392L, and 394W, and (ii) a light chain comprising a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:76, and a kappa constant region comprising C κ mutations 124R and 178R; and
(B) an anti-LAG3 antigen-binding fragment comprising (i) a heavy chain comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:97, and an IgG1 constant region comprising CH1 mutation 181K, and CH3 mutations 350V, 351Y, 405A, and 407V, and (ii) a light chain comprising a light chain variable region comprising the amino acid sequence of SEQ ID NO:99, and a kappa constant region comprising C κ mutations 124E, 131T, 178Y, and 180E,
wherein the mutations are in EU numbering.
15. An anti-PD-1/LAG-3 bispecific antibody comprising:
(A) an anti-PD-1 antigen-binding fragment comprising (i) a heavy chain comprising a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:93, and an IgG1 constant region comprising CH1 mutations 145E, 147T, 175E, and 183L, and (ii) a light chain comprising a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:76, and a kappa constant region comprising C κ mutations 124R and 178R; and
(B) an anti-LAG3 antigen-binding fragment comprising (i) a heavy chain comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:97, and an IgG1 constant region comprising CH1 mutation 181K, and (ii) a light chain comprising a light chain variable region comprising the amino acid sequence of SEQ ID NO:99, and a kappa constant region comprising C κ mutations 124E, 131T, 178Y, and 180E;
wherein the IgG1 heavy chain constant regions of the anti-PD-1 and anti-LAG3 antigen-binding fragments further comprise pairs of CH3 mutations selected from the group consisting of: 351Y/405A/407V and 366I/392M/394W; 351Y/405A/407V and 366L/392L/394W; and 351Y/405A/407V and 366L/392M/394W, and wherein the mutations are in EU numbering.
16. An anti-PD-1/LAG3 bispecific antibody comprising:
(A) an anti-PD-1 heavy chain comprising the amino acid sequence of SEQ ID NO:101, and a light chain comprising the amino acid sequence of SEQ ID NO:100, and
(B) an anti-LAG3 heavy chain comprising the amino acid sequence of SEQ ID NO:96, and a light chain comprising the amino acid sequence of SEQ ID NO:98.
17. An anti-PD1/LAG3 bispecific antibody comprising:
(A) an anti-PD-1 heavy chain variable region comprising the amino acid sequence of SEQ ID NO:109, and a light chain variable region comprising the amino acid sequence of SEQ ID NO:111, and
(B) an anti-LAG3 heavy chain variable region comprising the amino acid sequence of SEQ ID NO:105, and a light chain variable region comprising the amino acid sequence of SEQ ID NO:107.
18. The anti-PD-1/LAG3 bispecific antibody of claim 17 , comprising:
(A) an anti-PD-1 heavy chain comprising the amino acid sequence of SEQ ID NO:108, and a light chain comprising the amino acid sequence of SEQ ID NO:110, and
(B) an anti-LAG3 heavy chain comprising the amino acid sequence of SEQ ID NO:104, and a light chain comprising the amino acid sequence of SEQ ID NO:106.
19. The bispecific antibody or antigen-binding fragment of claim 10 , wherein the antibody or antigen-binding fragment thereof comprises a glycosylation pattern characteristic of expression by a CHO cell.